The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts

BACKGROUND: Anti-fibrotic drugs such as pirfenidone have been developed for the treatment of idiopathic pulmonary fibrosis. Because activated fibroblasts in inflammatory conditions have similar characteristics as cancer-associated fibroblasts (CAFs) and CAFs contribute actively to the malignant phen...

Descripción completa

Detalles Bibliográficos
Autores principales: Mediavilla-Varela, Melanie, Boateng, Kingsley, Noyes, David, Antonia, Scott J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776434/
https://www.ncbi.nlm.nih.gov/pubmed/26935219
http://dx.doi.org/10.1186/s12885-016-2162-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4776434/
https://www.ncbi.nlm.nih.gov/pubmed/26935219
http://dx.doi.org/10.1186/s12885-016-2162-z

Ejemplares similares